Cancer is an important disease which jeopardizes people's health

and also one of the important causes of human death. With the progress of technology

the treatments of cancer are no longer limited to the surgical treatment

chemotherapy and traditional radiotherapy. Endocrine therapy

immunotherapy

targeted therapy and other novel therapeutic methods have also been developed. Although there are many therapies for cancer

the effect of cancer treatment is unsatisfactory. Poor therapeutic effect of cancer treatment is associated with difficulty of early diagnosis

deficiency of remedy and some other factors. Moreover

the emergence of resistance to the tumor treatment has also brought great obstacles to cancer therapy. In recent years

many studies have shown that there is a close relationship between high mobility group protein B1 (HMGB1) and tumor chemotherapy resistance. Some researchers have found that HMGB1 can promote tumor therapy resistance by participating in cell autophagy

DNA damage repair

resistance to cell apoptosis

promotion of cell proliferation and angiogenesis

enhancement of immune escape and inflammation. In this paper

the recent research progress of the correlation between HMGB1 and tumor therapy resistance were reviewed.